People

The People

Governance grade: C. Lyka Labs is effectively controlled by Ipca Laboratories (40.98% of equity directly; ~58.16% counted in the promoter block), which turned a minority co-control arrangement into a commanding stake by converting preferential warrants at ₹139.50 while the open-market price collapsed from ₹129 to ₹60. The CEO was paid ₹5.27 crore in a year the standalone company earned ₹8.2 Cr of profit — the single loudest alignment problem on the page. The board checks the boxes for SEBI compliance, but one of the "non-executive" directors is an executive director of the 41%-holder, and the long-serving CFO owns 1,050 shares. This is a controlled-company situation where minority protection rests almost entirely on Ipca's self-interest, not on board independence.

**The one question that decides everything here:** does Ipca intend to take Lyka private at a fair price, or run it as a captive contract manufacturer indefinitely? Every governance signal — warrant pricing to promoter, ₹5.27 Cr CEO pay on tiny profits, the in-progress merger with Lyka Exports — points toward long-term captive status.

The People Running This Company

Six people decide what happens at Lyka. One is the co-controlling shareholder represented on the board; one is the executive CEO paid more than the company earns; one is the 43-year-tenure CFO who owns almost no stock; three are independent directors whose composition is transitioning.

Promoter holding (%)

58.16

Ipca direct stake (%)

40.98

CEO Kunal Gandhi stake (%)

9.79

Employees (FY25)

499

No Results

**The invisible seventh seat.** Ipca Laboratories (40.98% direct, part of the promoter group) does not sit on the Lyka board as a corporate entity, but it controls the company through share ownership, Prashant Godha's non-executive directorship, and a joint management control agreement entered in 2021–22 when Ipca acquired 26.57% from the earlier Shah family promoters. Every major capital action in the last three years — warrant issue, preferential allotment at ₹139.50, pending Lyka Exports merger, related-party sales of ₹26 Cr — has been to or with Ipca.

What They Get Paid

Only two people draw executive compensation. The gap between them — and between the CEO and the P&L — is where the alignment question lives.

No Results

**Red flag — pay is not earned, it is granted.** CEO compensation rose 48% in FY25 despite the company posting just ₹8.2 Cr standalone profit (recovering from a ₹2.3 Cr loss). Over FY22–FY25, cumulative standalone PAT is ~₹46 Cr; cumulative CEO pay is ~₹14 Cr — roughly **30 paise of CEO comp for every rupee of profit**. The ₹1.40 Cr "unavailed privilege leave" lump sum inside FY25 pay is the kind of retrospective adjustment proxy advisers ordinarily flag; the approving N&R Committee met only twice during the year.

Median employee remuneration was flat at 0.0% in FY25 while managerial remuneration rose 29.49%. The general workforce got a 6.73% raise; the median number dragged to zero likely because of mix-shift or attrition in higher-paid roles.

Are They Aligned?

Ownership and control

The cap table is dominated by one entity. Ipca moved from 36.34% to 40.98% in FY25 by converting warrants; the full promoter block sits at 58.16%. The 10.94 lakh shares that moved out of Nehal Gandhi's name (founder-family, relative of the CEO) and into Kunal Gandhi's own name during FY25 is an intra-family transfer — not a sale to the market. The Gandhi family promoter bloc (CEO + relatives + Enai Trading) holds ~17.3% today.

**Control swung in 2021–22.** The Ipca stake — via open offer, block deals and joint management agreement with the prior Shah family promoters — rebased promoter holding from 19.88% to 47.79% in a single year, then stair-stepped upward through two warrant rounds (FY24: +24 lakh shares, FY25: +26 lakh shares, both at ₹139.50 to Ipca). The original Gandhi family stake has been diluted down from the 2017 level; control now sits with the corporate promoter, not the founding family.

Insider buying vs selling

Insider activity is one-directional and concentrated: Ipca buys, no insiders sell on the open market. Over FY24–FY25 Ipca absorbed 50 lakh warrants at ₹139.50 — a ~₹70 Cr commitment at the then-market price but one that is now about 133% above the current ₹59.80 market. That is genuine cash put in, and it is the single largest piece of positive alignment evidence on the page.

No Results

Dilution and option grants

Shareholders have seen about 16% dilution in three years, and a new ESOS is pending.

Lyka ESOS 2025 (proposed at the FY26 AGM) allows up to 1,00,000 options per employee, maximum 75% discount to market, vesting 1–5 years, exercise within 5 years post-vest. Promoters and any 10%+ shareholder are explicitly excluded — so the scheme cannot give Kunal Gandhi more stock. The scale is small (well under 1% of equity per individual), but the 75% discount provision means grants could be made at deep discounts; minority shareholders should watch the specific grant terms when they are issued.

This is the most sensitive area of the page. FY25 related-party activity with Ipca was ₹25.9 Cr of sales, ₹36.3 Cr of equity issuance (fresh capital in), and ₹27.5 Cr of loan repayment (Ipca reduced its related-party lending). The direction of these flows is favourable to Lyka's balance sheet — Ipca put in equity and took out debt — but the ~20% revenue concentration with the controlling shareholder is a structural dependency, not a choice.

No Results

**Merger in progress:** Lyka Exports Limited (subsidiary) is merging into Lyka Labs under an NCLT-approved scheme; shareholder and creditor meetings were held in March 2025. This simplifies the structure and reduces one layer of related-party complexity, but the merger is not yet fully operative.

Capital allocation

Capital discipline is mixed. Debt has come down sharply (total borrowings roughly halved from the FY21 peak), but the company has not paid a dividend in several years and the warrants plus preferential issues have absorbed nearly all the equity raised. Management is funding the new Lyophilization Phase-I line (~₹22 Cr capex) primarily out of Ipca's warrant cash — effectively, the controlling shareholder is capitalising the company in exchange for a larger stake.

Skin-in-the-game score

Skin-in-the-game score (1 = worst, 10 = best)

Why 4 out of 10. The corporate promoter (Ipca) has meaningful, hard-cash skin in the game — roughly ₹70 Cr of warrant money at ₹139.50 against today's ₹60 price — and its incentive to make Lyka succeed is real. The CEO holds 9.79% worth ~₹21 Cr; that is genuine but it was built by intra-family transfer, not by open-market buying. The CFO's 1,050 shares after 43 years is a red flag. No independent director holds any meaningful stake. Net: alignment is asymmetric — Ipca wins, minority wins only if Ipca wants it to.

Board Quality

SEBI box-checks pass. The substance is thinner.

No Results

No Results

**The independence gap.** Three of seven directors are classified non-executive but are not truly independent: Prashant Godha is an Executive Director of Ipca (the 40.98% shareholder), and Shashil Mendonsa sits as a generic non-executive without published independence attestation. Functionally, Ipca-aligned voices outnumber truly independent ones if the CEO votes with the promoter block — which he normally would, since he is part of the promoter group. On conflicted matters (pay, warrants, RPTs) minority protection rests on the three independents: Jain, Golas, and Shah (soon Yadav).

The Verdict

Governance grade

Positives.

Ipca Laboratories has put real cash into the company at ₹139.50 per share — against today's ₹60 price, that is a demonstrated long-horizon commitment, not a drive-by investor. Control is uncontested, so there is no proxy-fight or hostile-takeover discount to worry about. The audit report is clean — no qualifications, no fraud disclosures, no SEBI regulatory actions surfaced in public reporting. Secretarial audit flagged only late MCA filings (procedural). The CEO owns 9.79%, which is not founder-level but meaningful, and at ₹21 Cr it is real money. Independent chairman, separate from CEO. Woman director requirement met with a forensic-audit-qualified CA replacement (Archana Yadav) coming in mid-2025.

Concerns.

CEO pay is not earned: ₹5.27 Cr on ₹8.2 Cr of standalone PAT is a ratio no reasonable proxy adviser would wave through. The ₹1.40 Cr leave-encashment lump sum inside the number is the kind of adjustment that tends to recur. Board independence is nominal: 3 of 7 are genuinely independent; one "non-executive" is literally an Ipca executive director. Minority protection relies entirely on Ipca's self-interest — there is no activist shareholder, no institutional owner with a stick, and retail holds 41%. If Ipca decides to delist Lyka at ₹60–70, there is no natural counterweight arguing for ₹139.50. The CFO owns 1,050 shares after 43 years — the finance chief has essentially no personal exposure to the books he runs.

One thing that would upgrade the grade to B: a public commitment from the board to cap CEO cash compensation at 3x median employee pay until standalone PAT exceeds ₹25 Cr — OR an explicit statement from Ipca on whether it intends to take Lyka private and at what price.

One thing that would downgrade the grade to D: any future preferential issue to Ipca at a price below the current market (minority dilution at an unfair price), or a related-party revenue share above 30% without member-approved pricing disclosure.

**Bottom line.** Lyka's governance is passable because the controlling shareholder has historically treated the company fairly — equity in at premium prices, debt reduced, clean audit. It is not good because the structural checks minority shareholders normally rely on — independent board majority, market-linked pay, equity ownership across the executive team — are absent. This is a "trust the promoter, not the system" setup. Size the position accordingly.